Metoprolol tartrate and Iron binding capacity total decreased - a phase IV clinical study of FDA data

Summary:

Iron binding capacity total decreased is found among people who take Metoprolol tartrate, especially for people who are female, 60+ old.

The phase IV clinical study analyzes which people take Metoprolol tartrate and have Iron binding capacity total decreased. It is created by eHealthMe based on reports of 71,517 people who have side effects when taking Metoprolol tartrate from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.



On Jun, 03, 2022

71,517 people reported to have side effects when taking Metoprolol tartrate.
Among them, 8 people (0.01%) have Iron binding capacity total decreased.


What is Metoprolol tartrate?

Metoprolol tartrate has active ingredients of metoprolol tartrate. It is often used in high blood pressure. eHealthMe is studying from 76,613 Metoprolol tartrate users for its effectiveness, alternative drugs and more.

What is Iron binding capacity total decreased?

Iron binding capacity total decreased is found to be associated with 269 drugs and 90 conditions by eHealthMe.

Number of Metoprolol tartrate and Iron binding capacity total decreased reports submitted per year:

Could Metoprolol tartrate cause Iron binding capacity total decreased?

Gender of people who have Iron binding capacity total decreased when taking Metoprolol tartrate *:

  • female: 87.5 %
  • male: 12.5 %

Age of people who have Iron binding capacity total decreased when taking Metoprolol tartrate *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 50 %
  • 60+: 50 %

Common drugs people take besides Metoprolol tartrate *:

  1. Famotidine: 4 people, 50.00%
  2. Gabapentin: 4 people, 50.00%
  3. Ibuprofen: 4 people, 50.00%
  4. Cerebyx: 4 people, 50.00%
  5. Prednisone: 4 people, 50.00%
  6. Nystatin: 4 people, 50.00%
  7. Lorazepam: 4 people, 50.00%
  8. Nifedipine: 4 people, 50.00%
  9. Femara: 3 people, 37.50%
  10. Ibrance: 3 people, 37.50%

Common side effects people have besides Iron binding capacity total decreased *:

  1. Blood Sodium Decreased: 7 people, 87.50%
  2. Pleural Effusion (water on the lungs): 7 people, 87.50%
  3. Haemoglobin Decreased: 6 people, 75.00%
  4. Blood Glucose Increased: 6 people, 75.00%
  5. Acute Kidney Failure: 6 people, 75.00%
  6. Haematocrit Decreased: 6 people, 75.00%
  7. Fatigue (feeling of tiredness): 5 people, 62.50%
  8. Hypotension (abnormally low blood pressure): 5 people, 62.50%
  9. Pain: 5 people, 62.50%
  10. Stress And Anxiety: 5 people, 62.50%

Common conditions people have *:

  1. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 4 people, 50.00%
  2. Breast Cancer Metastatic: 3 people, 37.50%
  3. Diabetes: 1 person, 12.50%

* Approximation only. Some reports may have incomplete information.

Do you take Metoprolol tartrate and have Iron binding capacity total decreased?

Check whether Iron binding capacity total decreased is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of Metoprolol tartrate:

Iron binding capacity total decreased treatments and more:

COVID vaccines that are related to Iron binding capacity total decreased:

How severe was Iron binding capacity total decreased and when was it recovered:

Expand to all the drugs that have ingredients of metoprolol tartrate:

All the drugs that are associated with Iron binding capacity total decreased:

All the conditions that are associated with Iron binding capacity total decreased:

How the study uses the data?

The study uses data from the FDA. It is based on metoprolol tartrate (the active ingredients of Metoprolol tartrate) and Metoprolol tartrate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: